The AAPS journalTherapeutic EquivalencyMethylphenidateHumansDelayed-Action PreparationsAttention Deficit Disorder with Hyperactivity
The Role of Early Exposure Metrics (pAUC0-3h and Cmax,0-3h) in Assessing the Bioequivalence of Methylphenidate Extended-release Products_A Sensitivity Analysis.
Li-Feng Hsu
Published: 202510.1208/s12248-025-01158-y
Abstract
Methylphenidate extended-release (ER) products are used in the treatment of attention-deficit/hyperactivity disorder (ADHD). These products exhibit diverse pharmacokinetic (PK) profiles that influence early systemic exposure and clinical response. To…
Preview only. Read the full abstract at the source